Sentrx Announces New Director of Pharmacovigilance Operations
Sentrx announced today that Suzanne Tepper, PharmD, RPh, has joined the firm as Director of Pharmacovigilance Operations. Dr. Tepper held drug safety management positions at Aventis, Johnson & Johnson, and Schering-Plough. She will be responsible for the people, processes and technology associated with the intake and investigation of adverse event cases.
Little Falls, NJ (PRWEB) May 10, 2006
Sentrx, the leading provider of technology-enabled drug safety and pharmacovigilance services, announced today that Suzanne Tepper, PharmD, RPh, has joined the firm as Director of Pharmacovigilance Operations.
Dr. Tepper has extensive experience in pharmacovigilance processes and drug safety systems. She held management positions at Aventis, formerly Hoechst Marion Roussel, in their Global Pharmacovigilance and Epidemiology group. There she led multi-disciplined teams to successfully complete several important projects, including the safety data migration associated with the merger that created Aventis; the conversion to the Medical Dictionary for Regulatory Affairs (MedDRA); and implementation of the electronic submission of Individual Case Safety Reports (ICSRs) to the FDA. Tepper also held positions at Johnson & Johnson in their Benefit Risk Management group and in Global Pharmacovigilance at Schering-Plough Research Institute, improving regulatory reporting and signal detection programs.
Prior to entering the pharmaceutical industry, Dr. Tepper owned a retail pharmacy for nearly ten years and also worked in the hospital pharmacy setting. She is a registered pharmacist and holds a Doctorate of Pharmacy, a Bachelor of Science in Pharmacy, and a Bachelor of Arts in Special Education.
“We are pleased to add Suzanne Tepper to the executive team,” said Joseph Albano, Chief Executive Officer of Sentrx. “Her entrepreneurial spirit, along with her background in corporate pharmacovigilance processes, drug safety systems, patient counseling and physician interaction, is an ideal combination. She will use all these experiences at Sentrx as we support our clients in clinical safety, post-marketing surveillance and risk management.”
“Sentrx is a company I have respected for many years, and I am excited about the opportunity to combine my clinical knowledge and business experience in daily activity,” said Dr. Tepper. “I look forward to meeting the needs of diverse clients in the midst of a dynamic regulatory environment.”
Dr. Tepper will be responsible for the people, processes and technology associated with the intake and investigation of adverse event cases and report directly to Dr. Ralph Bobo, Executive Vice President of Pharmacovigilance Practices and Senior Medical Safety Officer.
Sentrx is a leading provider of technology-enabled solutions and services for global drug safety. Its mission is to help pharmaceutical, biotechnology, medical device, and consumer health companies demonstrate the safety of their products and respond rapidly to any potential risks detected. Through its multilingual Safety Response Center, Sentrx delivers a unique combination of highly skilled people, exclusive technology, and best practices in drug safety monitoring. To learn more about Sentrx, please visit their website at www. sentrx. com, or call 1-888-399-8032, extension 261.
# # #